Baird analyst Eric Coldwell lowered the firm’s price target on Accendra Health (ACH) to $5 from $7 and keeps an Outperform rating on the shares. The firm updated its model following the closing of the sale of PHS and its rebranding from Owens & Minor to Accendra Health.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACH: